In response to this complex issue, the treatment options for CML have expanded to include second-line TKIs, such as Dasatinib [10], Nilotinib [11], and Bosutinib, each with distinct mechanisms of action against various BCR::ABL1 mutations. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.